Future perspectives in hepatocellular carcinoma

Digestive and Liver Disease

Volumn 42, Issue SUPPL. 3, 2010, Pages S302-S309

  Wörns, Marcus A ^a   Galle, Peter R ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Hepatocellular carcinoma; Individualized medicine; Multidisciplinary treatment

Indexed keywords

AFLATOXIN B1; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CETUXIMAB; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; HEPATITIS B VACCINE; LAPATINIB; OXALIPLATIN; SORAFENIB; SUNITINIB; YTTRIUM 90; PROTEIN KINASE INHIBITOR;

ABLATION THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL TRIAL; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; VACCINATION; CARCINOMA, HEPATOCELLULAR; FIBROSIS; FORECASTING; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; PERSONALIZED MEDICINE; TRENDS;

ABLATION TECHNIQUES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FIBROSIS; FORECASTING; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PROTEIN KINASE INHIBITORS;

EID: 77953776656     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60521-X     Document Type: Article

References (49)

1. El-Serag HB, Rudolph KL Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576.
2. Llovet JM, Bru C, Bruix J Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19(3):329-338.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390.
4. Bruix J, Sherman M Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
5. Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137(1):110-118.
6. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the non-invasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008, 47(1):97-104.
7. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006, 131(6):1758-1767.
8. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35(3):421-430.
9. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41(4):707-716.
10. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40(3):667-676.
11. Villanueva A, Toffanin S, Llovet JM Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol 2008, 20(4):444-453.
12. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38(2):200-207.
13. Llovet JM, Bruix J Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008, 48(Suppl l):S20-S37.
14. Sherman M Recurrence of hepatocellular carcinoma. N Engl J Med 2008, 359(19):2045-2047.
15. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006, 44(6):1543-1554.
16. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359(19):1995-2004.
17. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(1l):693-699.
18. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33(6):1394-1403.
19. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10(1):35-43.
20. Otto G, Herber S, Heise M, et al. Response to transarterial chemoem-bolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006, 12(8):1260-1267.
21. Yao FY, Kerlan RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008, 48(3):819-827.
22. Chapman WC, Majella Doyle MB, Stuart JE, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008, 248(4):617-625.
23. Schwartz M, Dvorchik I, Roayaie S, et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol 2008, 49(4):581-588.
24. Lencioni R, Crocetti L, Petruzzi P, et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 2008, 49(2):217-222.
25. Marelli L, Stigliano R, Triantes C, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006, 32(8):594-606.
26. Llovet JM, Bruix J Systematic review of randomized trials for un-resectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37(2):429-442.
27. Marelli L, Stigliano R, Triantes C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective?. A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007, 30(1):6-25.
28. Várela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46(3):474-481.
29. Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of an-giogenesis and invasiveness. Am J Gastroenterol 2008, 103(4):914-921.
30. Strebel BM, Dufour JF Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008, 8(1l):1743-1749.
31. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138(1):52-64.
32. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008, 47(1):71-81.
33. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009, 9(8):1920-1928.
34. Lopez PM, Villanueva A, Llovet JM Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006, 23(1l):1535-1547.
35. Llovet JM, Bruix J Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48(4):1312-1327.
36. Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27(1):55-76.
37. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(1):25-34.
38. Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009, 14(1):70-76.
39. Worns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009, 43(5):489-495.
40. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009, 115(2):428-436.
41. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27(18):3027-3035.
42. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009, 27(6):843-850.
43. Raoul JL, Finn RS, Kang YK, et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2009, 27(15s). Abstract 4577.
44. Treiber G mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 2009, 9(2):247-261.
45. Worns MA, Weinmann A, Schuchmann M, et al. Systemic therapies in hepatocellular carcinoma. Dig Dis 2009, 27(2):175-188.
46. Boucher E, Forner A, Reig M, et al. New drugs for the treatment of hepatocellular carcinoma. Liver Int 2009, 29(Suppl 1):148-158.
47. Abou-Alfa GK, Amadori D, Santero A, et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis?. J Clin Oncol 2008, 26(May 20 Suppl). Abstract 4518.
48. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Nati Cancer Inst 2008, 100(10):698-711.
49. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231.